Abstract: The disclosure provides methods for storage solutions for preserving DNA methylation patters over a period of time. The disclosure also provides for methods of using methylated DNA stored in such storage solutions.

Abstract: The disclosure provides methods for storage solutions for preserving DNA methylation patterns over a period of time. The disclosure also provides for methods of using methylated DNA stored in such storage solutions.

Abstract: Provided herein are methods and a device for collecting biological samples. In particular, the present disclosure relates to a device designed to specifically capture samples within the target areas of a patient for specific cell collection for particular diagnosis.

Abstract: The disclosure provides methods for storage solutions for preserving DNA methylation patterns over a period of time. The disclosure also provides for methods of using methylated DNA stored in such storage solutions.

Abstract: A method for collecting a cell sample, including eosinophil white blood cells in a patient is provided. The method includes advancing to a location in an esophagus associated with eosinophilic esophagitis (EoE), a device provided with a collection portion having a first axial end portion and an inflatable second axial end portion. Thereafter, axially moving the second axial end portion, relative to the first axial end portion, from a collapsed position within the first axial end portion into an expanded position out from the first axial end portion. Once the second axial end portion is in the expanded position, allowing it to engage the location associated with EoE to collect a sample of cells.

Abstract: The present invention provides a method of reducing the quantity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quantity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.

Abstract: Enteral Feeding Intolerance (EFI) can be efficaciously treated by administration of therapeutically effective doses of ulimorelin every 8 hours (three times a day). Therapeutic benefit can be obtained from single and consecutive daily dosing, including for periods of up to a week or longer.

Abstract: The present invention provides a method of reducing the quantity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quantity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.

Abstract: Enteral Feeding Intolerance (EFI) can be efficaciously treated by administration of therapeutically effective doses of ulimorelin every 8 hours (three times a day). Therapeutic benefit can be obtained from single and consecutive daily dosing, including for periods of up to a week or longer.

Abstract: The present invention provides a method of reducing the quantity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quantity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.

Abstract: The present invention provides a method of reducing the quanitity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quanitity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.

Abstract: The present invention provides a method of reducing the quanitity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quanitity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.

Abstract: The present invention provides a method of reducing the quanitity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quanitity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.

Abstract: The present invention provides a method of reducing the quanitity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quanitity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.

Abstract: Methods for administering beta-adrenergic inverse agonists with improved pharmacokinetic profiles for the treatment of pulmonary airway diseases are disclosed. The beta adrenergic inverse agonists are formulated in a controlled-release formulation comprising: (1) a beta-adrenergic inverse agonist in a therapeutically effective quantity; and (2) at least one agent that controls release of the beta-adrenergic inverse agonist resulting in a pharmacokinetic profile that minimizes acute detrimental reduction in airway function with the first dose and with each successive dose. This pharmacokinetic profile typically results in slow release of the drug into the bloodstream resulting in a large average Tmax>4 hours. The controlled-release formulation may consist of multilayered matrix or erosional tablets, gastric-retention tablets, osmotic pump oral formulations, multiparticulate capsules or tablets or dermal patch.